… 20 years have we developed cancer therapeutics based on our knowledge of cancer
biology. For example, the work of Elion and Hitchings (4, 5) led to targeting the enzymes of DNA …

… need, and many potential cancer targets remain undrugged. In this review we assess the
status of the discovery and development of small-molecule cancer therapeutics. We show how …

… therapeutics… molecules of Twist signaling pathways have also been identified. Development
of potential treatment strategies by targeting Twist has a great promise in cancer therapeutics…

… referred to as “targeted therapeutics,” which target specific protein kinases … cancer. Herein,
we examine the cardiotoxicity of targeted therapeutics, focusing on the underlying molecular …

… The hope is that identification of therapeutic targets … of cancer therapeutics established
over the past 50 years remain valid. Combination treatment regimens covering multiple targets …

… ing pathway is dysregulated in many human cancers and is an attractive candidate for
targeted cancer therapy. A staurosporine analogue, K252a is a broad-spectrum kinase inhibitor …

… Duplex DNA has become a favoured target for selective therapeutics, with the insight into
recognition codes to target unambiguously either the minor or major groove of DNA. Thus, …

… of cancer, agents aimed at novel molecular targets are required. Colorectal and many other
cancers … promise for the development of new anti-cancer drugs. Our study describes recent …

… that, although they are directed toward a specific molecular target, they simultaneously inhibit
multiple signaling pathways on which cancer cells depend for growth and survival, thereby …

… In this paper, we provide an overview of targeted anticancer therapies with small molecule
… cancer cell. To draw attention to the fact that kinase inhibition in targeted cancer therapeutics …